Hyper Corporation (065650) Fair Value & Analysis
Healthcare · KR · Market cap 25.5B KRW
Fair value as of: Jun 24, 2026
Analysis
Hyper Corporation (065650) currently trades at 1,960 KRW, while our model-based Fair Value estimate is 2,528 KRW — implying the stock looks roughly 29.0% undervalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low) — always confirm before acting.
About the company
Hyper Corporation Inc., a clinical stage biopharmaceutical company, focuses on the development of Alzheimer's disease (AD) and neuropathic pain treatments, and AD diagnostics. Its products under development include TRPV1 Antagonist and TRPV1 Agonist for neuropathic pain; and anti-oligomerization of beta-amyloid, receptor for advanced glycation endproduct modulator, and early diagnosis kits for AD. The company wholesales and retails electronic devices, small home appliances, TVs, routers, and PC peripherals, such as gaming monitors, mouse, and wheels; keyboards; headsets; webcams; and sound bars, as well as provides online contents. In addition, it manufactures and supplies frozen and room temperature convenience food products, such as frozen sticky rice and fish cakes, tteokbokki sauce, and raw materials for sauce under the Memories of Elementary School Tteokbokki, Newtro, and K-TOWN brands. The company was formerly known as Medifron DBT Co., Ltd. and changed its name to Hyper Corpo…
Open the full interactive analysis →
Similar stocks
Frequently asked questions
Is Hyper Corporation (065650) undervalued?
What is the fair value of 065650?
What is the quality score of 065650?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.